The CRISPR/Cas9-edited EHMT1 Knockout MES-OV Polyclonal Cells provide a pooled population of MES-OV cells carrying targeted disruption of the EHMT1 gene. This polyclonal knockout model is designed for studying EHMT1 loss-of-function in the context of ovarian clear cell carcinoma, without clonal selection. The knockout cell population facilitates investigation of epigenetic regulation and transcriptional repression mechanisms dependent on EHMT1 activity.
MES-OV is a human ovarian clear cell carcinoma cell line, derived from patient tumor tissue and widely used as a model for ovarian clear cell adenocarcinoma. This adherent epithelial line retains key characteristics of the primary cancer, including relevant genetic alterations and growth properties. It is particularly valuable for preclinical studies of ovarian cancer biology and for testing therapeutic interventions targeting epigenetic regulators.
EHMT1 encodes a histone lysine methyltransferase that specifically catalyzes mono- and dimethylation of histone H3 at lysine 9 (H3K9me1/2), marks associated with transcriptional silencing and heterochromatin formation. EHMT1 functions in obligate complexes with its homolog EHMT2/G9a and is recruited to chromatin by transcription factors such as REST, which silences neuronal genes (e.g., BDNF, SYN1) in non-neuronal tissues. The enzyme also interacts with HP1 proteins, MPP8, and chromatin remodeling factors to maintain repressive chromatin states. EHMT1 directly regulates the tumor suppressor CDKN1A and operates within a pathway involving REST, CoREST, and H3K9 methylation to control gene expression programs.
In ovarian clear cell carcinoma cells, EHMT1-mediated H3K9 methylation may contribute to the epigenetic silencing of tumor suppressor genes and maintenance of the malignant phenotype. Disruption of EHMT1 in the MES-OV background allows researchers to assess its role in cancer cell proliferation, differentiation, and response to epigenetic therapies. The polyclonal knockout population offers a convenient system for evaluating the functional consequences of EHMT1 loss without the artifacts of clonal selection, providing a more representative model of heterogeneous tumor cell populations.
Typical research applications include western blotting for H3K9me1/2 levels, RT-qPCR analysis of downstream targets such as CDKN1A and neuronal genes, ChIP-qPCR to measure H3K9me2 enrichment at specific loci, and immunofluorescence for HP1 foci formation as a readout of heterochromatin integrity. The cells are also suitable for functional genomics screens, cell proliferation and drug sensitivity assays with EHMT inhibitors, and mechanistic studies of REST and EHMT2 interaction networks in ovarian cancer. For further details, please contact Ascent Research.
